Cision PR Newswire
IART INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Integra LifeSciences Holdings Corporation Investors to Inquire About Securities Class Action Investigation - IART
News provided byRosen Law Firm, P.A.
May 26, 2023, 7:13 PM ET
NEW YORK, May 26, 2023 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Integra LifeSciences Holdings Corporation (NASDAQ: IART) resulting from allegations that Integra may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased Integra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=16467 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email email@example.com or firstname.lastname@example.org for information on the class action.
WHAT IS THIS ABOUT: On May 23, 2023, before the market opened, Integra filed a report with the SEC that stated, "Integra LifeSciences Holdings Corporation (the "Company"), after consultation with the U.S. Food and Drug Administration (the "FDA"), initiated a voluntary global recall of all products manufactured in its Boston, Massachusetts facility (the "Boston facility") distributed between March 1, 2018 and May 22, 2023 (the "voluntary recall"). As a result, the Company concluded on May 22, 2023 that it expects it will incur an impairment charge related to the write-off of inventories, net, of approximately $22 million. The Company expects this charge will be recorded in the quarter ending June 30, 2023." In addition, the report stated, "[t]he Company identified through an internal investigation process in its Boston facility deviations with endotoxin testing that may have resulted in the release of products with higher levels of endotoxins than permitted by the product specifications. Higher levels of endotoxins can induce an immune response, leading to a post-operative fever. Although there is no specific indication of any reported product complaints related to high endotoxin levels, the Company, in accordance with its commitment to patient safety and product quality, has decided to initiate the voluntary recall and extend the temporary halt of manufacturing at its Boston facility to implement additional detection and quality controls. The Company expects to resume manufacturing at its Boston facility following implementation of such controls. The voluntary recall includes the SurgiMend, PriMatrix, Revize™ and TissueMend™ products. The Company expects that the voluntary recall and manufacturing stoppage will have the greatest impact on the Tissue Technologies segment, including Private Label, and has revised guidance. For the second quarter, the Company expects reported revenues in the range of $372 million to $376 million and adjusted earnings per diluted share to be in the range of $0.55 to $0.59. While it is difficult to estimate at this time the impact of the voluntary recall for the full year, if the manufacturing stoppage continued through the remainder of 2023, the Company estimates full-year revenue and adjusted earnings per share guidance provided during the Company's April earnings announcement would be negatively affected by approximately $60 million and $0.35, respectively. Products manufactured at the Boston facility represent approximately 5% of the Company's consolidated revenues. The Company expects to provide updated details on its full-year guidance during its second quarter 2023 financial results conference call."
On this news, Integra's stock price fell $10.24 per share, or 20.19% to close at $40.48 per share on May 23, 2023. The following day, Integra's stock price fell a further $1.33 per share, or 3.28%, to close at $39.15 per share.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
View original content to download multimedia:https://www.prnewswire.com/news-releases/iart-investor-news-rosen-trusted-investor-counsel-encourages-integra-lifesciences-holdings-corporation-investors-to-inquire-about-securities-class-action-investigation--iart-301836038.html
SOURCE Rosen Law Firm, P.A.
NOTE: This content is not written by or endorsed by "WAVY", its advertisers, or Nexstar Media Inc.